









市場行情
/
股票
/
nasdaq-mgtx
/

MeiraGTx Holdings PLC

MGTX

7.970USD

-0.300-3.63%

收盤 12/26, 16:00（美東）報價延遲15分鐘

641.42M總市值

虧損本益比TTM



MeiraGTx Holdings PLC

7.970

-0.300-3.63%

概覽公司財務分析

概覽

公司

財務

分析

關於 MeiraGTx Holdings PLC 公司

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

MeiraGTx Holdings PLC簡介



公司代碼MGTX

公司名稱MeiraGTx Holdings PLC

上市日期Jun 08, 2018

CEOForbes (Alexandria)

員工數量381

證券類型Ordinary Share

年結日Jun 08

公司地址655 Third Avenue

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編10017

電話16468607985

網址https://meiragtx.com/

公司代碼MGTX

上市日期Jun 08, 2018

CEOForbes (Alexandria)

MeiraGTx Holdings PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Alexandria Forbes, Ph.D.

President, Chief Executive Officer, Director

1.31M

-3.49%

Mr. Richard Giroux

Chief Financial Officer, Chief Operating Officer

919.65K

-2.54%

Dr. Stuart Naylor, Ph.D.

Chief Development Officer

623.29K

Mr. Thomas E. Shenk, Ph.D.

Independent Director

157.48K

Mr. Robert K. Zeldin, M.D.

Chief Medical Officer

136.52K

+7.14%

Dr. Keith R. Harris, Ph.D.

Independent Chairman of the Board

125.00K

+150.00%

Mr. Robert J. Wollin, J.D.

General Counsel, Secretary

26.15K

-16.05%

Ms. Ellen Hukkelhoven, Ph.D.

Independent Director

Ms. Nicole Seligman

Independent Director

Mr. Neil F. J. (Lord) Mendoza

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Alexandria Forbes, Ph.D.

President, Chief Executive Officer, Director

1.31M

-3.49%

Mr. Richard Giroux

Chief Financial Officer, Chief Operating Officer

919.65K

-2.54%

Dr. Stuart Naylor, Ph.D.

Chief Development Officer

623.29K

Mr. Thomas E. Shenk, Ph.D.

Independent Director

157.48K

Mr. Robert K. Zeldin, M.D.

Chief Medical Officer

136.52K

+7.14%

Dr. Keith R. Harris, Ph.D.

Independent Chairman of the Board

125.00K

+150.00%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Perceptive Advisors LLC

15.69%

Sanofi SA

15.15%

Johnson & Johnson Innovation-JJDC, Inc.

8.25%

Adage Capital Management, L.P.

5.20%

Prosight Capital

5.08%

其他

50.63%

持股股東

佔比

Perceptive Advisors LLC

15.69%

Sanofi SA

15.15%

Johnson & Johnson Innovation-JJDC, Inc.

8.25%

Adage Capital Management, L.P.

5.20%

Prosight Capital

5.08%

其他

50.63%

股東類型

持股股東

佔比

Hedge Fund

26.94%

Corporation

16.02%

Private Equity

15.69%

Venture Capital

8.29%

Investment Advisor

7.12%

Investment Advisor/Hedge Fund

4.38%

Individual Investor

4.17%

Research Firm

2.26%

Pension Fund

0.09%

其他

15.04%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

228

52.30M

65.02%

+2.51M

2025Q2

231

67.71M

84.26%

+4.10M

2025Q1

245

80.15M

99.86%

+3.86M

2024Q4

246

77.41M

99.87%

+22.10M

2024Q3

250

64.74M

84.14%

+9.72M

2024Q2

251

52.33M

80.03%

+4.22M

2024Q1

254

51.24M

78.85%

+2.58M

2023Q4

253

50.76M

80.27%

+3.66M

2023Q3

255

41.86M

71.40%

-5.70M

2023Q2

256

41.99M

71.79%

-2.93M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Perceptive Advisors LLC

12.63M

15.69%

+45.00K

+0.36%

Jun 30, 2025

Sanofi SA

12.20M

15.16%

Jun 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

6.64M

8.26%

Jun 30, 2025

Adage Capital Management, L.P.

6.03M

7.5%

+400.00K

+7.10%

Jun 30, 2025

Prosight Capital

4.59M

5.7%

+895.88K

+24.27%

Jun 30, 2025

Rubric Capital Management LP

3.73M

4.63%

+1.95M

+109.78%

Jun 30, 2025

683 Capital Management LLC

2.69M

3.34%

+115.00K

+4.47%

Jun 30, 2025

Millennium Management LLC

785.18K

0.98%

+785.18K

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.48M

3.09%

-243.04K

-8.91%

Jun 30, 2025

J. Goldman & Co., L.P.

2.04M

2.54%

+885.81K

+76.44%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

iShares Micro-Cap ETF

0.07%

ProShares Ultra Nasdaq Biotechnology

0.07%

Invesco Nasdaq Biotechnology ETF

0.07%

Goldman Sachs Innovate Equity ETF

0.06%

Vanguard US Momentum Factor ETF

0.04%

iShares Biotechnology ETF

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Russell 2000 Growth ETF

0.02%

SPDR S&P International Small Cap ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

iShares Micro-Cap ETF

佔比0.07%

ProShares Ultra Nasdaq Biotechnology

佔比0.07%

Invesco Nasdaq Biotechnology ETF

佔比0.07%

Goldman Sachs Innovate Equity ETF

佔比0.06%

Vanguard US Momentum Factor ETF

佔比0.04%

iShares Biotechnology ETF

佔比0.04%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0.02%

SPDR S&P International Small Cap ETF

佔比0.02%

iShares Russell 2000 Value ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

MeiraGTx Holdings PLC的前五大股東是誰？



MeiraGTx Holdings PLC的前五大股東如下：
Perceptive Advisors LLC
持有股份：12.63M
佔總股份比例：15.69%。
Sanofi SA
持有股份：12.20M
佔總股份比例：15.16%。
Johnson & Johnson Innovation-JJDC, Inc.
持有股份：6.64M
佔總股份比例：8.26%。
Adage Capital Management, L.P.
持有股份：6.03M
佔總股份比例：7.50%。
Prosight Capital
持有股份：4.59M
佔總股份比例：5.70%。